HIV-1 protease inhibitors.
Deeks
S G
SG
University of California, San Francisco, USA.
Volberding
P A
PA
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015195:Drug Design; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D007546:Isoquinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019888:Nelfinavir; D019438:Ritonavir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019258:Saquinavir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D013451:Sulfonic Acids; D019469:Indinavir; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir